Trastuzumab deruxtecan shows early promise in patients with non-breast/gastric cancers

Bottom Line: A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study. Journal in Which the Study was Published: Cancer Discovery, a journal of the American Association for Cancer Research Author: Lead author: Junji Tsurutani, MD, PhD, medical oncologist at…